Rani Therapeutics Price Target Maintained at Buy by Chardan Capital
Chardan Capital has maintained its 'Buy' rating and price target for Rani Therapeutics, reflecting continued analyst confidence in the company.
Stocks · News reference
Rani Therapeutics Scheduled to Announce Q3 2026 Financial Results
Rani Therapeutics Holdings, Inc. is scheduled to release its financial results for the third quarter of 2026 on November 5, 2026.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Why Ericsson Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
Ericsson shares surged 10.9% premarket after beating Q3 earnings and sales estimates; other small-cap stocks saw sharp gains and losses.
Rani Therapeutics Joins FDA Emerging Technology Platform
Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the RaniPill® Capsule™ platform technology has been accepted into the
HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $11 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy and maintains $11 price target.
This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Top analysts changed outlook on top names. See analyst ratings page for all changes.
Chardan Capital Initiates Coverage On Rani Therapeutics Hldgs with Buy Rating, Announces Price Target of $6
Chardan Capital analyst Andreas Argyrides initiates coverage on Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy rating and announces Price Target of $6.